search
Back to results

The DISSECT Study: Effect of Peri-aDventItial SMA diSsECtion on Margin sTatus During Pancreaticoduodenectomy for Resectable Pancreatic Cancer

Primary Purpose

Pancreatic Adenocarcinoma

Status
Recruiting
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
No Periadventitial dissection of the SMA
Periadventitial dissection of the SMA
Sponsored by
University Hospital Birmingham NHS Foundation Trust
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Pancreatic Adenocarcinoma focused on measuring pancreatic cancer, SMA dissection, Superior mesenteric artery, margin status

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • All adult (≥ 18 years old) patients with a non-metastatic (based on NCCN definition) on imaging pancreatic tumour of the head or uncinate process treated with a pancreaticoduodenectomy

Exclusion Criteria:

  1. All paediatric patients (< 18 years old)
  2. Patients that cannot provide consent
  3. All borderline, locally advanced and metastatic pancreatic tumours on imaging (based on NCCN criteria)
  4. All patients with a cytological or histological diagnosis of cholangiocarcinoma, ampullary and duodenal carcinoma
  5. All patients with benign disease or dysplasia with no evidence of malignancy

Sites / Locations

  • University Hospitals Birmingham NHS Foundation TrustRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Periadventitial dissection

NO periadventitial dissection

Arm Description

For the patients randomised for peri-adventitial dissection the right side of the SMA should be completely clear from lymphoneural tissue for at least 180 degrees on right side and from "angle" of the artery to the level of inferior border of the uncinate process.

For patients randomised to NO peri-adventitial dissection, the lymphoneural tissue around the SMA should be left intact

Outcomes

Primary Outcome Measures

SMA margin status
Rate of R0 resection (defined as no tumour within 1mm from the SMA margin)

Secondary Outcome Measures

Length of stay
Number of days to discharge (day 0 being the day of the operation)
Complications
categorised by clavien-dindo (grade 1 to 5, higher score = worse)
adjuvant treatment
percentage of patients receiving adjuvant chemotherapy, type and duration.
Overall survival
The length of time (in months) from day of diagnosis to death or last follow up
Disease free survival
length of time (in months) from day of resection until diagnosis of recurrence or last follow up

Full Information

First Posted
May 13, 2021
Last Updated
May 14, 2023
Sponsor
University Hospital Birmingham NHS Foundation Trust
search

1. Study Identification

Unique Protocol Identification Number
NCT04902352
Brief Title
The DISSECT Study: Effect of Peri-aDventItial SMA diSsECtion on Margin sTatus During Pancreaticoduodenectomy for Resectable Pancreatic Cancer
Official Title
Effect of Peri-adventitial SMA Dissection on Margin Status During Pancreaticoduodenectomy for Resectable Pancreatic Cancer
Study Type
Interventional

2. Study Status

Record Verification Date
May 2023
Overall Recruitment Status
Recruiting
Study Start Date
April 6, 2021 (Actual)
Primary Completion Date
October 6, 2023 (Anticipated)
Study Completion Date
October 6, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University Hospital Birmingham NHS Foundation Trust

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
There is a high rate of R1 resection following patients undergoing pancreaticoduodenectomy for pancreatic cancer. The most commonly positive margin is the SMA. Peri-adventitial dissection has been proposed as an effective method of achieving R0 margins. There is lack of standardisation of the proposed technique and no grade 1 evidence to support routine use of this technique. The goal of this randomised controlled trial is to investigate the role of routine peri-adventitial dissection on the SMA margin status.
Detailed Description
Pancreatic cancer is the 4th cause of cancer death in Europe. With the existing treatments the overall 5-year survival remains 8%. For patients with non-metastatic disease, many are conventionally judged unresectable with just 10-20% eligible for upfront surgery and a 5-year survival of 10-30%. Microscopically positive margins (R1) have been associated with poorer survival of patients undergoing pancreaticoduodenectomy. The incidence of R1 varies between 16-79% in the published literature and the median survival for patients undergoing R0 resections is between 19-21 months versus 9-13 months for patients undergoing R1. Therefore, to investigate strategies to decrease the rate of R1 resection is crucial to significantly improve the patient survival1. The SMA margin is positive in 47-77% of these resections, even when the margin is "clear" on the pre-operative staging CT2,4. Many different techniques are in practice and have been described for this part of the pancreaticoduodenectomy procedure, including the use of diathermy and ties, energy devices such as Ligasure, and staplers. The main denominator is staying close to the SMA and removing the so called "mesopancreas"3.Peri-adventitial arterial dissection is a technique that has been a commune practise in several pancreatic centres and has been proposed as an effective surgical technique to achieve R0 margins. On the other hand, SMA dissection may theoretically increase the risk of acute haemorrhage, vascular injury, and thrombosis, development of pseudo-aneurysms or persistent chyle leak due to the extensive lymphoneural dissection. Furthermore, the published evidence reveal variability in the definition of a "positive margin", as well as the lack of accurate description of the surgical technique in the majority of the studies, with only about 25% of the studies reporting the use of the technique4. Moreover, none of the published studies have documented standardisation in the use of the technique with regards to the extent of the periadventitial dissection on the SMA, longitudinally and circumferentially. In the University Hospitals of Birmingham NHS Trust, pancreatic surgery is centralised in Queen Elizabeth Hospital. Peri-adventitial dissection is selectively performed in cases where there is a close relation of the tumour to the arteries in an effort to achieve an R0 resection. Routine practice of peri-adventitial dissection during pancreaticoduodenectomy for resectable tumours has been performed in a subset of patients based on surgeon's preference. The results suggest a R1 rate of 20%, with SMA margin positivity 5%, compared to a rate of 44% margin positivity within the unit, with 54% SMA R1 rate. Furthermore, complication rates are comparable to the average described by the unit's results and published literature (20.8% of grade B and above complications as per the Clavien-Dindo classification). More specifically, there have been no incidences of vascular related injury or complication related to the technique; or persistent chyle leak (one episode of chyle leak grade A recorded that was managed conservatively). The goal of this prospective study is to investigate the role of routine peri-adventitial dissection on the SMA margin status. Primary outcome is SMA margin status. Secondary outcomes are: length of stay, complications, overall survival, disease free survival and adjuvant treatment uptake. This will be a two arm, randomised 1:1 (periadventitial dissection : no periadventitial dissection) study. A pilot phase will determine feasibility to proceed with the rest of the trial and to determine: Feasibility of patient recruiting and randomisation Feasibility and reproducibility of the technique Feasibility of use of intraoperative photography Intraoperative and postoperative complication rate and severity (Clavien-Dindo classification) Positive SMA margin status rate Feasibility criteria to be met in order to proceed with the rest of the trial: Recruitment of at least 20 patients in 6 months (both arms) Periadventitial dissection technique to be performed in at least 80% of the randomised patients to that arm as documented by intraoperative photography Increase in the complication rate no more than 10% For the full trial a sample size of 51 patients per arm has been based on a margin positivity of 44%, based on the unit's results, and expected 60% reduction (expected R1 18%) at power 80% (type A error 0.05).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pancreatic Adenocarcinoma
Keywords
pancreatic cancer, SMA dissection, Superior mesenteric artery, margin status

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Randomised Control Trial
Masking
ParticipantInvestigatorOutcomes Assessor
Masking Description
Sealed envelope system for allocation of intervention Master list held by third party, researcher and surgical team aware of intervention Intervention NOT documented in notes making clinical follow up team, investigator and outcomes assessor blind to arm allocated
Allocation
Randomized
Enrollment
102 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Periadventitial dissection
Arm Type
Experimental
Arm Description
For the patients randomised for peri-adventitial dissection the right side of the SMA should be completely clear from lymphoneural tissue for at least 180 degrees on right side and from "angle" of the artery to the level of inferior border of the uncinate process.
Arm Title
NO periadventitial dissection
Arm Type
Active Comparator
Arm Description
For patients randomised to NO peri-adventitial dissection, the lymphoneural tissue around the SMA should be left intact
Intervention Type
Procedure
Intervention Name(s)
No Periadventitial dissection of the SMA
Intervention Description
lymphoneural tissue around SMA left intact
Intervention Type
Procedure
Intervention Name(s)
Periadventitial dissection of the SMA
Intervention Description
For the patients randomised for peri-adventitial dissection the right side of the SMA should be completely clear from lymphoneural tissue for at least 180 degrees on right side and from "angle" of the artery to the level of inferior border of the uncinate process. In the presence of an accessory or replaced right hepatic artery the peri-adventitial dissection should also be carried out around this vessel as well.
Primary Outcome Measure Information:
Title
SMA margin status
Description
Rate of R0 resection (defined as no tumour within 1mm from the SMA margin)
Time Frame
Recorded at histological examination estimated 2 weeks post-operatively
Secondary Outcome Measure Information:
Title
Length of stay
Description
Number of days to discharge (day 0 being the day of the operation)
Time Frame
Recorded at patient discharge (monitored by research team) and analysed at an expected time frame of 2 years (study end)
Title
Complications
Description
categorised by clavien-dindo (grade 1 to 5, higher score = worse)
Time Frame
90 days
Title
adjuvant treatment
Description
percentage of patients receiving adjuvant chemotherapy, type and duration.
Time Frame
within 1 year of surgery
Title
Overall survival
Description
The length of time (in months) from day of diagnosis to death or last follow up
Time Frame
Analysis at 5 years from start of trial
Title
Disease free survival
Description
length of time (in months) from day of resection until diagnosis of recurrence or last follow up
Time Frame
Analysis at 5 years from start of trial

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: All adult (≥ 18 years old) patients with a non-metastatic (based on NCCN definition) on imaging pancreatic tumour of the head or uncinate process treated with a pancreaticoduodenectomy Exclusion Criteria: All paediatric patients (< 18 years old) Patients that cannot provide consent All borderline, locally advanced and metastatic pancreatic tumours on imaging (based on NCCN criteria) All patients with a cytological or histological diagnosis of cholangiocarcinoma, ampullary and duodenal carcinoma All patients with benign disease or dysplasia with no evidence of malignancy
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Nikolaos A Chatzizacharias, FRCS
Phone
07787731126
Email
Nikolaos.Chatzizacharias@uhb.nhs.uk
First Name & Middle Initial & Last Name or Official Title & Degree
Sarah F Powell-Brett, MRCS
Phone
07887754856
Email
sarah.powell-brett1@nhs.net
Facility Information:
Facility Name
University Hospitals Birmingham NHS Foundation Trust
City
Birmingham
State/Province
County (Optional)
ZIP/Postal Code
B15 2GW
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Nikolas A Chatzizacharias, FRCS
Phone
07787731126
Email
Nikolaos.Chatzizacharias@uhb.nhs.uk
First Name & Middle Initial & Last Name & Degree
Sarah F Powell-Brett, MRCS
Phone
07887754856
Email
sarah.powell-brett1@nhs.net

12. IPD Sharing Statement

Learn more about this trial

The DISSECT Study: Effect of Peri-aDventItial SMA diSsECtion on Margin sTatus During Pancreaticoduodenectomy for Resectable Pancreatic Cancer

We'll reach out to this number within 24 hrs